Curidium Medica says it discovered the existence of four unique diagnostic gene expression profiles in blood samples from schizophrenia/bipolar disorder patients.
The company used its Homomatrix tool to analyze 115 patients and matched controls. It found that each patient/control was a member of only one of four subgroups. Each subgroup was associated with a unique and finite number of genes. The genes identified in each subgroup include known and novel drug targets and biomarkers.
The company is in the process of determining the specificity and sensitivity of a potential blood diagnostic test.